14 completed, 3 terminated, 1 active not recruiting, 1 not yet recruiting. 21 Phase 2, 5 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 21 | Completed 14, Terminated 3, Active not recruiting 1, Not yet recruiting 1, Recruiting 1, Withdrawn 1 |
| Phase 1 | 5 | Completed 3, Terminated 1, Withdrawn 1 |
Follow Leukemia, Mast-Cell: new trials by email Literature Review of Leukemia, Mast-Cell trials Research Report on Leukemia, Mast-Cell
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Depletion of CD45RA Positive Naive T Cells for the Prevention of Graft Versus Host Disease in Older Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia or Myelodysplastic Syndrome Allogeneic CD34+-enriched and CD45RA-depleted PBSCs, Biospecimen Collection, Bone Marrow Aspiration - Acute Biphenotypic Leukemia, Acute Leukemia | Phase 2 | Not yet recruiting | Fred Hutchinson Cancer Center | 52 | 2027-01-01 | 2026-09-14 |
| (Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis bezuclastinib - Advanced Systemic Mastocytosis (AdvSM), SM With an Associated Hematologic Neoplasm (SM-AHN) | Phase 2 | Recruiting | Cogent Biosciences, Inc. | 140 | 2021-11-09 | 2026-09-15 |
| GTB-3550 Tri-Specific Killer Engager (TriKE®) for High Risk Hematological Malignancies GTB-3550 TriKE® Phase I, GTB-3550 TriKE® Phase II - High-risk Myelodysplastic Syndromes, Acute Myelogenous Leukemia | Phase 1 / Phase 2 | Terminated | GT Biopharma, Inc. | 12 | 2020-01-01 | 2022-11-10 |
| Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant Total-Body Irradiation, Thiotepa, Fludarabine - Acute Biphenotypic Leukemia, Acute Leukemia | Phase 2 | Active not recruiting | Fred Hutchinson Cancer Center | 45 | 2019-08-29 | 2026-09-25 |
| (PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis Avapritinib - Advanced Systemic Mastocytosis, Aggressive Systemic Mastocytosis | Phase 2 | Completed | Blueprint Medicines Corporation | 107 | 2018-11-21 | 2026-10-20 |
| Ibrutinib in Treating Patients With Advanced Systemic Mastocytosis Ibrutinib - Aggressive Systemic Mastocytosis, Mast Cell Leukemia | Phase 2 | Terminated | Jason Robert Gotlib | 4 | 2015-03-01 | 2018-09-20 |
| Brentuximab Vedotin in Treating Patients With Advanced Systemic Mastocytosis or Mast Cell Leukemia Brentuximab vedotin - Aggressive Systemic Mastocytosis, Mast Cell Leukemia | Phase 2 | Completed | Jason Robert Gotlib | 10 | 2013-09-01 | 2019-01-29 |
| Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies deferasirox, laboratory biomarker analysis, enzyme-linked immunosorbent assay - Acute Undifferentiated Leukemia, Adult Acute Lymphoblastic Leukemia in Remission | Phase 2 | Completed | Wake Forest University Health Sciences | 16 | 2011-01-01 | 2018-09-07 |
| Donor Natural Killer Cells After Donor Stem Cell Transplant in Treating Patients With Advanced Cancer donor natural killer cell infusion - Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders | Phase 1 / Phase 2 | Completed | Asan Medical Center | 47 | 2009-01-01 | 2013-02-20 |
| Efficacy and Safety of Midostaurin in Patients With Aggressive Systemic Mastocytosis or Mast Cell Leukemia Midostaurin (PKC412) - Leukemia | Phase 2 | Completed | Novartis Pharmaceuticals | 116 | 2008-10-13 | 2018-11-15 |
| Epoetin Alfa or Darbepoetin Alfa in Treating Patients With Anemia Caused by Chemotherapy darbepoetin alfa, epoetin alfa, fatigue assessment and management - Anemia, Leukemia | Phase 2 | Completed | Mayo Clinic | 239 | 2007-05-01 | 2017-02-10 |
| Sunitinib in Treating Patients With Idiopathic Myelofibrosis sunitinib malate - Accelerated Phase Chronic Myelogenous Leukemia, Acute Undifferentiated Leukemia | Phase 2 | Terminated | National Cancer Institute (NCI) | 14 | 2006-09-01 | 2014-05-28 |
| Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD Total lymphoid irradiation, Rituximab, Anti-thymoglobulin, rabbit (ATG, rabbit ATG) - Leukemia, Mast-Cell, Mantle-cell Lymphoma | Phase 2 | Completed | Stanford University | 36 | 2005-06-01 | 2017-11-28 |
| Phase 2 Midostaurin in Aggressive Systemic Mastocytosis and Mast Cell Leukemia Midostaurin - Systemic Mastocytosis, Aggressive (ASM), Leukemia, Mast Cell | Phase 2 | Completed | Jason Robert Gotlib | 26 | 2005-03-01 | 2018-09-20 |
| Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer alemtuzumab, total-body irradiation, fludarabine phosphate - Acute Undifferentiated Leukemia, Adult Acute Lymphoblastic Leukemia in Remission | Phase 2 | Completed | Fred Hutchinson Cancer Center | 12 | 2005-03-01 | 2017-05-30 |
| Ontak (Denileukin Diftitox) in Patients With Systemic Mastocytosis (SM) Ontak (Denileukin Diftitox) - Leukemia, Systemic Mastocytosis | Phase 2 | Completed | M.D. Anderson Cancer Center | 8 | 2004-07-01 | 2012-02-08 |
| Donor Stem Cell Transplant After Busulfan, Fludarabine, and Antithymocyte Globulin in Treating Patients With Hematological Cancer anti-thymocyte globulin, busulfan, fludarabine phosphate - Leukemia, Myelodysplastic Syndromes | Phase 2 | Completed | Asan Medical Center | 52 | 2003-01-01 | 2013-03-26 |
| Doxorubicin Hydrochloride Liposome and Bortezomib in Treating Patients With Refractory Hematologic Cancer or Malignant Solid Tumor or Metastatic Breast Cancer PS-341, Doxil, Velcade - Breast Cancer, Leukemia | Phase 1 / Phase 2 | Completed | UNC Lineberger Comprehensive Cancer Center | 107 | 2001-05-01 | 2012-05-18 |
| Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases Imatinib mesylate - Life Threatening Diseases | Phase 2 | Completed | Novartis Pharmaceuticals | 185 | 2001-02-01 | 2016-11-18 |
| Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer total-body irradiation, fludarabine phosphate, cyclosporine - Acute Undifferentiated Leukemia, Adult Nasal Type Extranodal NK/T-cell Lymphoma | Phase 1 / Phase 2 | Completed | Fred Hutchinson Cancer Center | 21 | 2000-05-01 | 2020-01-21 |
Showing 20 of 21. Sign in to see all of them.
Leukemia, Myeloid, Acute (11) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (11) · Leukemia, Biphenotypic, Acute (10) · Burkitt Lymphoma (9) · Leukemia (8) · Leukemia, Lymphocytic, Chronic, B-Cell (8) · Leukemia, Myelomonocytic, Chronic (8) · Lymphoma, Mantle-Cell (8) · Mastocytosis, Systemic (8) · Multiple Myeloma (8) · Myeloproliferative Disorders (8) · Hodgkin Disease (7) · Immunoblastic Lymphadenopathy (7) · Leukemia, Hairy Cell (7)
Hemic and Lymphatic Diseases (21) · Mast Cell Activation Disorders (21) · Neoplasms by Histologic Type (21) · Hematologic Diseases (20) · Immune System Diseases (20) · Neoplasms (20) · Leukemia, Myeloid (19) · Mastocytosis (19) · Bone Marrow Diseases (13) · Immunoproliferative Disorders (13) · Leukemia (13) · Lymphatic Diseases (13) · Mastocytosis, Systemic (13) · Chronic Disease (11) · Disease Attributes (11)
Whole-Body Irradiation (4) · fludarabine phosphate (4) · Cyclosporine (3) · Mycophenolic Acid (3) · Busulfan (2) · Cyclophosphamide (2) · Methotrexate (2) · Peripheral Blood Stem Cell Transplantation (2) · Therapeutics (2) · fludarabine (2) · midostaurin (2) · Acetaminophen (1) · Alemtuzumab (1) · Antilymphocyte Serum (1) · Biopsy (1)
Fred Hutchinson Cancer Center (4) · Jason Robert Gotlib (3) · Asan Medical Center (2) · M.D. Anderson Cancer Center (2) · Novartis Pharmaceuticals (2) · Blueprint Medicines Corporation (1) · Cogent Biosciences, Inc. (1) · GT Biopharma, Inc. (1) · Mayo Clinic (1) · National Cancer Institute (NCI) (1) · Stanford University (1) · UNC Lineberger Comprehensive Cancer Center (1) · Wake Forest University Health Sciences (1)
United States (17) · Italy (4) · Austria (3) · Canada (3) · France (3) · Germany (3) · Netherlands (3) · Norway (3) · Poland (3) · United Kingdom (3) · Australia (2) · Belgium (2) · South Korea (2) · Spain (2) · Denmark (1)
Jason Gotlib (2) · Kyoo H. Lee, MD (2) · Brenda Sandmaier (1) · Charles L. Loprinzi, M.D. (1) · David Maloney (1) · David Miklos (1) · Elizabeth C. Dees, MD (1) · Jason Robert Gotlib (1) · Jorge Cortes, MD (1) · Marie Bleakley (1) · Mark B Juckett, MD (1) · Mary Ann Knovich, MD (1) · Michael Heinrich, MD (1) · Patrick Chaftari, MD (1)
PMID 27355533, PMID 18327587, PMID 19451433, PMID 21523798, PMID 22563089, PMID 28744009, PMID 31350306, PMID 32437738, PMID 32499241, PMID 33049057, PMID 34873345, PMID 35640224, PMID 35790816, PMID 39649724, PMID 41604606
P30CA015704 (3), P01CA018029 (2), 2008 (1), 2017 (1), N01CM62202 (1), P01CA049605 (1), P01CA078902 (1), P30CA015083 (1), P30CA124435 (1)